tiprankstipranks
Henry Schein (CH:HS2)
:HS2

Henry Schein (HS2) Price & Analysis

0 Followers

HS2 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Recurring Technology RevenueThe technology portfolio adds recurring, higher-quality revenue alongside distribution, deepening customer relationships and improving predictability. Subscriber growth and rising revenue per customer support a durable platform for cross-selling software and services.
Scale And Market Share GainsStrong merchandise growth across geographies indicates that Henry Schein’s distribution scale, supplier relationships, and broad product range remain competitive. Share gains can reinforce purchasing leverage and customer retention, supporting sustained revenue expansion.
Guidance And Operating Improvement PlanThe raised outlook and quantified improvement program provide evidence of operational execution rather than relying solely on market growth. Gross-profit and G&A initiatives could support earnings resilience and margin improvement over the next several quarters.
Bears Say
Persistent Net Margin CompressionRevenue growth has not translated proportionately into bottom-line profitability, indicating weaker earnings conversion than earlier periods. Sustained margin pressure would limit internal investment capacity and make future earnings more dependent on efficiency actions.
Higher Financial LeverageThe materially higher debt burden reduces financial flexibility compared with prior years and can constrain acquisitions, technology investment, or shareholder returns. It also increases sensitivity to weaker operating performance even though equity and ROE remain positive.
Equipment And Diagnostic Demand PressureWeakness in equipment and point-of-care diagnostics highlights uneven demand across the portfolio and may persist beyond a single quarter. These categories can also carry different margins and purchasing cycles, creating mix and growth challenges for the broader business.

Henry Schein News

HS2 FAQ

What was Henry Schein’s price range in the past 12 months?
Currently, no data Available
What is Henry Schein’s market cap?
Henry Schein’s market cap is CHF7.90B.
    When is Henry Schein’s upcoming earnings report date?
    Henry Schein’s upcoming earnings report date is Nov 03, 2026 which is in 73 days.
      How were Henry Schein’s earnings last quarter?
      Henry Schein released its earnings results on Aug 04, 2026. The company reported CHF1.018 earnings per share for the quarter, beating the consensus estimate of CHF0.994 by CHF0.024.
        Is Henry Schein overvalued?
        According to Wall Street analysts Henry Schein’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Henry Schein pay dividends?
          Henry Schein does not currently pay dividends.
          What is Henry Schein’s EPS estimate?
          Henry Schein’s EPS estimate is 1.09.
            How many shares outstanding does Henry Schein have?
            Currently, no data Available
            What happened to Henry Schein’s price movement after its last earnings report?
            Henry Schein reported an EPS of CHF1.018 in its last earnings report, beating expectations of CHF0.994. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Henry Schein?
              Currently, no hedge funds are holding shares in CH:HS2
              What is the TipRanks Smart Score and how is it calculated?
              Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                Company Description

                Henry Schein

                Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

                Henry Schein (HS2) Earnings & Revenues

                HS2 Company Deck

                HS2 Earnings Call

                Q2 2026
                0:00 / 0:00
                Earnings Call Sentiment|Positive
                The call presented a predominantly positive operational and financial update: solid top-line growth (6.7%), expanding margins, double-digit non-GAAP EPS growth (15.5%), strong adjusted EBITDA growth (12.7%), and raised full-year guidance. Management reinforced a clear value-creation program with specific savings targets ($125M run-rate by end-2026; $200M+ over time) and early implementation steps producing measurable benefits. Technology and recurring-revenue businesses (Dentrix Ascend / Henry Schein One) showed notable strength and strategic potential. Near-term headwinds include a small decline in U.S. dental equipment, lower point-of-care diagnostic demand, meaningful Q2 restructuring charges ($29M), and reduced remeasurement gains versus prior year, which constrain GAAP clarity and EPS flow-through. Overall, the positive metrics, guidance raise, and credible execution plan outweigh the localized challenges and one-time costs.View all CH:HS2 earnings summaries

                HS2 Revenue Breakdown

                84.48%84.48%11.71%5.12%-1.31%
                84.48% Global Distribution and Value-Added Services
                11.71% Global Specialty Products
                5.12% Global Technology
                -1.31% Eliminations
                tipranks

                HS2 Stock 12 Month Forecast

                Average Price Target

                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
                Similar Stocks
                Company
                Price & Change
                Follow
                Cencora
                Cardinal Health
                McKesson
                Prestige Consumer Healthcare
                Popular Stocks